EP1514106A4 - Gezielte therapeutische proteine - Google Patents
Gezielte therapeutische proteineInfo
- Publication number
- EP1514106A4 EP1514106A4 EP03736779A EP03736779A EP1514106A4 EP 1514106 A4 EP1514106 A4 EP 1514106A4 EP 03736779 A EP03736779 A EP 03736779A EP 03736779 A EP03736779 A EP 03736779A EP 1514106 A4 EP1514106 A4 EP 1514106A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapeutic proteins
- targeted therapeutic
- targeted
- proteins
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US272531 | 1994-07-11 | ||
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US384452P | 2002-05-29 | ||
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US386019P | 2002-06-05 | ||
| US40881602P | 2002-09-06 | 2002-09-06 | |
| US408816P | 2002-09-06 | ||
| US10/272,531 US20040005309A1 (en) | 2002-05-29 | 2002-10-16 | Targeted therapeutic proteins |
| US44573403P | 2003-02-06 | 2003-02-06 | |
| US445734P | 2003-02-06 | ||
| PCT/US2003/017211 WO2003102583A1 (en) | 2002-05-29 | 2003-05-29 | Targeted therapeutic proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1514106A1 EP1514106A1 (de) | 2005-03-16 |
| EP1514106A4 true EP1514106A4 (de) | 2007-05-09 |
Family
ID=29716364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03736779A Withdrawn EP1514106A4 (de) | 2002-05-29 | 2003-05-29 | Gezielte therapeutische proteine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1514106A4 (de) |
| AU (1) | AU2003237314B2 (de) |
| CA (1) | CA2487815A1 (de) |
| WO (1) | WO2003102583A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| AU2002256423B2 (en) | 2001-04-30 | 2008-07-24 | Zystor Therapeutics, Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| ES2368941T3 (es) | 2003-01-06 | 2011-11-23 | Angiochem Inc. | Angiopep-1, compuestos relacionados y utilizaciones correspondientes. |
| JP4914224B2 (ja) * | 2004-02-10 | 2012-04-11 | バイオマリン ファーマシューティカル インコーポレイテッド | 酸性αグルコシダーゼおよびそのフラグメント |
| EP1818395A1 (de) | 2006-02-08 | 2007-08-15 | Diatos | Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| JP5901877B2 (ja) | 2007-07-27 | 2016-04-13 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物 |
| US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| EP2346906A4 (de) | 2008-10-15 | 2013-04-24 | Angiochem Inc | Konjugate aus glp-1-agonisten und ihre verwendung |
| JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
| WO2010069074A1 (en) | 2008-12-17 | 2010-06-24 | Universite Du Quebec A Montreal | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| EP2421562B1 (de) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Behandlung von ovarialkarzinom mit einem an ein angiopep-2-analogon konjugierten antitumorwirkstoff |
| ES2758827T3 (es) | 2009-06-17 | 2020-05-06 | Biomarin Pharm Inc | Formulaciones para enzimas lisosómicas |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| ES2725200T3 (es) | 2009-10-09 | 2019-09-20 | Armagen Inc | Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC |
| UA115648C2 (uk) | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Доставка терапевтичних агентів до цнс |
| NZ702801A (en) | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| RU2012154576A (ru) | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
| BR112012033216B1 (pt) | 2010-06-25 | 2022-10-11 | Shire Human Genetic Therapies, Inc | Uso de uma formulação estável compreendendo uma proteína arilsulfatase a (asa) e formulação estável para administração intratecal |
| PL2593131T3 (pl) | 2010-06-25 | 2020-01-31 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun |
| CN104857504A (zh) | 2010-06-25 | 2015-08-26 | 夏尔人类遗传性治疗公司 | 芳基硫酸酯酶a cns递送的方法和组合物 |
| EP2785837A4 (de) * | 2011-12-01 | 2015-07-01 | Angiochem Inc | Gezielte enzymatische verbindungen und ihre verwendungen |
| MX2014006594A (es) * | 2011-12-01 | 2015-09-16 | Angiochem Inc | Compuestos de enzimas lisosomales apuntados. |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| MX2014015551A (es) * | 2012-06-15 | 2016-09-19 | Angiochem Inc | Compuestos iduronidasa apuntados. |
| DK3115372T3 (da) | 2012-11-27 | 2019-06-11 | Biomarin Pharm Inc | Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf |
| WO2014082184A1 (en) * | 2012-11-30 | 2014-06-05 | Angiochem Inc. | Targeted iduronate-2-sulfatase compounds |
| SI2991683T1 (sl) | 2013-05-02 | 2020-01-31 | Glykos Finland Oy | Konjugati glikoproteina ali glikana s toksično obremenitvijo |
| WO2014194428A1 (en) * | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted heparan sulfatase compounds |
| WO2016001485A1 (en) | 2014-06-30 | 2016-01-07 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| EP3220958A1 (de) * | 2014-10-24 | 2017-09-27 | Shire Human Genetic Therapies, Inc. | Lysosomes targeting von enzymen und verwendungen davon |
| CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| EP4275751A3 (de) | 2016-02-24 | 2023-12-27 | BioMarin Pharmaceutical Inc. | Verbesserte naglu-fusionsproteinformulierung |
| EP3898689A1 (de) | 2018-12-20 | 2021-10-27 | Armagen, Inc. | Reinigung von iduronat-2-sulfatase-immunoglobulin-fusionsprotein |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087510A2 (en) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
-
2003
- 2003-05-29 AU AU2003237314A patent/AU2003237314B2/en not_active Ceased
- 2003-05-29 EP EP03736779A patent/EP1514106A4/de not_active Withdrawn
- 2003-05-29 CA CA002487815A patent/CA2487815A1/en not_active Abandoned
- 2003-05-29 WO PCT/US2003/017211 patent/WO2003102583A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087510A2 (en) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
Non-Patent Citations (2)
| Title |
|---|
| NOLAN C M ET AL: "BINDING OF INSULIN-LIKE GROWTH FACTOR II (IGF-II) BY HUMAN CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR/IGF-II RECEPTOR EXPRESSED IN RECEPTOR-DEFICIENT MOUSE L CELLS", CELL REGULATION, BETHESDA,MD, US, vol. 1, no. 2, January 1990 (1990-01-01), pages 197 - 213, XP008053772, ISSN: 1044-2030 * |
| See also references of WO03102583A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2487815A1 (en) | 2003-12-11 |
| AU2003237314A1 (en) | 2003-12-19 |
| EP1514106A1 (de) | 2005-03-16 |
| WO2003102583A1 (en) | 2003-12-11 |
| AU2003237314B2 (en) | 2010-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1514106A4 (de) | Gezielte therapeutische proteine | |
| DK1543038T4 (da) | Proteinoprensning | |
| ATE465180T1 (de) | Therapeutische anti-igfr1-antikörper- kombinationen | |
| NO2017013I1 (no) | peginterferon beta-1a | |
| IS7499A (is) | Mennsk mótefni gegn beta-amýloíðpeptíðum | |
| ATE480567T1 (de) | Hochkonzentrierter antikörper und proteinformulierungen | |
| NO20040402L (no) | Peptidbaserte multimere malrettede kontrastmidler | |
| EP1597276A4 (de) | Therapeutische moleküle | |
| DK1495128T3 (da) | Forstærket proteinekspression i Bacillus | |
| EP1391209A4 (de) | Proteinzubereitung | |
| NO20033549D0 (no) | Terapeutiske bindingsmolekyler | |
| EP1570270A4 (de) | Therapeutische biokonjugate | |
| DK1490404T3 (da) | Laktoferrin | |
| EP1556403A4 (de) | Herstellung multimerer proteine | |
| DK1597171T3 (da) | Terapeutisk mikroskum | |
| EP1578774A4 (de) | Proteinaufreinigung | |
| DK1553950T3 (da) | Terapeutisk behandling | |
| DE10391058D2 (de) | Instantisierte Modifizierte Mehle | |
| NO20050689L (no) | Terapeutisk anvendelse | |
| EP1682572A4 (de) | Proteinexpression | |
| DE602004022136D1 (de) | Leukozyten stimulierende peptide | |
| FR2839258B1 (fr) | Deambulateur-siege | |
| NO20053512D0 (no) | IL-8-liknende proteiner | |
| NO20050436D0 (no) | Beta-lagnedbrytende peptider | |
| NO20052608D0 (no) | Midkinlignende protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041223 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076863 Country of ref document: HK |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BEVERLEY, STEPHEN, M. Inventor name: SLY, WILLIAM, S. Inventor name: LEBOWITZ, JONATHAN, H. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20070405 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOMARIN PHARMACEUTICAL INC. |
|
| 17Q | First examination report despatched |
Effective date: 20121031 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20130312 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1076863 Country of ref document: HK |